Search results for "Tyro"

showing 10 items of 816 documents

Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases.

2008

Cyclooxygenase 2-selective inhibitors (coxibs) and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with an increase in cardiovascular events. The current study was designed to test the effect of coxibs and nonselective NSAIDs on vascular superoxide and nitric oxide (NO) production. mRNA expression of endothelial NO synthase (eNOS) and of the vascular NADPH oxidases was studied in spontaneously hypertensive rats (SHR) and in human endothelial cells. The expression of Nox1, Nox2, Nox4, and p22phox was increased markedly by the nonselective NSAIDs diclofenac or naproxen and moderately by rofecoxib or celecoxib in the aorta and heart of SHR. The up-regulation of NADPH …

AdultMalePharmacologychemistry.chemical_compoundEnosRats Inbred SHRAnimalsHumansPharmacologyNADPH oxidasebiologyCyclooxygenase 2 InhibitorsNitrotyrosineAnti-Inflammatory Agents Non-SteroidalNOX4NADPH Oxidasesbiology.organism_classificationRatsUp-RegulationOxidative StresschemistryCyclooxygenase 2NOX1Apocynincardiovascular systembiology.proteinMolecular MedicineFemaleP22phoxEndothelium VascularPeroxynitriteThe Journal of pharmacology and experimental therapeutics
researchProduct

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated…

1996

Peptide epitopes derived from differentiation antigens of the melanocyte lineage have been identified in human melanomas and normal cultured melanocytes as targets for MHC-restricted cytotoxic T lymphocytes (CTL). Characterization of multiple CTL-defined antigenic determinants and the presence of corresponding precursor CTL open perspectives for the development of antigen-based vaccines. In the present study, we determined the CTL reactivity against melanoma-associated peptides derived from Melan A/MART-1, tyrosinase and gp100/Pmel17 in 10 HLA-A2+ melanoma patients and 10 healthy individuals. Then, we examined the immunological effects and toxicity of intradermal inoculation of synthetic me…

AdultMaleSignal peptideCancer ResearchInjections IntradermalMolecular Sequence DataTyrosinase Peptide10050 Institute of Pharmacology and Toxicology610 Medicine & healthchemical and pharmacologic phenomenaPeptideEpitopeImmune systemAntigenAntigens NeoplasmHumansCytotoxic T cellMedicine1306 Cancer ResearchHypersensitivity DelayedAmino Acid SequenceMelanomaCells CulturedAgedchemistry.chemical_classificationVaccinesbusiness.industryMiddle AgedNeoplasm ProteinsCTL*OncologychemistryImmunology570 Life sciences; biology2730 OncologyFemalebusinessMelanoma-Specific AntigensT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003

INTRODUCTION Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly a…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyMelperoneVenlafaxine HydrochlorideVenlafaxinePharmacologyMethylationPharmacokineticsOral administrationCytochrome P-450 CYP2D6 InhibitorsInternal medicineDextrorphanmedicineHumansDrug InteractionsPharmacology (medical)AgedRetrospective StudiesChemistryVenlafaxine HydrochlorideGeneral MedicineDextromethorphanMiddle AgedCyclohexanolsButyrophenonesPsychiatry and Mental healthEndocrinologyCytochrome P-450 CYP2D6Drug Therapy CombinationFemaleDrug MonitoringReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts.

2003

Abstract Background Decreased sensitivity to and increased tolerance for the effects of alcohol is a phenotype, which was shown to be associated with an increased risk for alcoholism in humans and was observed in protein tyrosine kinase (PTK) fyn knockout mice. Methods We performed an association study of genetic variations of PTK fyn in 430 alcohol-dependent patients and 365 unrelated control subjects from two independent samples. Results In a combined analysis, we found an association of alcohol dependence with the single nucleotide polymorphism (SNP) T137346C in the 5′ untranslated region (UTR) of the gene. A relevant association could be excluded for the remaining two informative SNPs. …

AdultMaleThreonineLinkage disequilibriumGenotypeGlycineSingle-nucleotide polymorphismBiologyProto-Oncogene Proteins c-fynPolymorphism Single NucleotideCohort StudiesFYNGene FrequencyProto-Oncogene ProteinsGenotypeSNPHumansCysteineAlleleBiological PsychiatryGeneticsAlanineChi-Square DistributionAlcohol dependenceGenetic VariationMiddle AgedAlcoholismCase-Control StudiesFemale5' Untranslated RegionsTyrosine kinaseBiological psychiatry
researchProduct

Novel rearrangements involving the RET gene in papillary thyroid carcinoma.

2018

Abstract Background In the field of gene fusions driving tumorigenesis in papillary thyroid carcinoma (PTC), rearrangement of the proto-oncogene RET is the most frequent alteration. Apart from the most common rearrangement of RET to CCDC6, more than 15 partner genes are yet reported. The landscape of RET rearrangements in PTC (“RET-PTC”) can notably be enlarged by modern targeted next-generation sequencing, indicating similarities between oncogenic pathways in other cancer types with identical genetic alterations. Methods Targeted next-generation sequencing was performed for two cases of BRAF-wild type PTC with confirmation of the results by Sanger sequencing. A “UniProt” database research …

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesendocrine systemCancer Researchendocrine system diseasesOncogene Proteins FusionBiologyRUN domainmedicine.disease_causeProto-Oncogene MasFusion gene03 medical and health sciencessymbols.namesake0302 clinical medicineGeneticsmedicineHumansThyroid NeoplasmsneoplasmsMolecular BiologyGeneSanger sequencingGene RearrangementProto-Oncogene Proteins c-retIntracellular Signaling Peptides and ProteinsCancerHigh-Throughput Nucleotide SequencingNuclear ProteinsProtein-Tyrosine Kinasesmedicine.diseaseLisH domainThyroid Cancer Papillary030220 oncology & carcinogenesisCancer researchsymbolsFemaleCarcinogenesisCarrier ProteinsTyrosine kinaseCancer genetics
researchProduct

Altered oxidative stress in overtrained athletes

2010

The purpose of the present study was to examine the relationship between oxidative stress and overtraining syndrome. Indicators of oxidative stress (plasma protein carbonyls, nitrotyrosine, and malondialdehyde) and antioxidant status (oxygen radical absorbance capacity) were measured in severely overtrained (two women, five men) and control athletes (five women, five men). Samples were collected from both groups at baseline (i.e. in the overtraining state of overtrained athletes) and after 6 months of recovery, both at rest and immediately after an exercise test to volitional exhaustion. At baseline, overtrained athletes had higher plasma protein carbonyls at rest than controls (mean differ…

AdultMalemalondialdehydemedicine.medical_specialtyAdolescentOxygen radical absorbance capacityRestPhysical Therapy Sports Therapy and RehabilitationPhysical exerciseliikuntamedicine.disease_causeProtein CarbonylationYoung Adultchemistry.chemical_compoundMalondialdehydeInternal medicineOxygen radical absorbance capacitymedicineHumansOrthopedics and Sports MedicineExercise physiologyExerciseFatigueprotein carbonylsnitrotyrosinenitrotyrosiiiniexercisebiologymalonialdehydiAthletesOvertrainingbusiness.industryNitrotyrosineBlood Proteinsbiology.organism_classificationmedicine.diseaseMalondialdehydeproteiini karbolyylitOxidative StressEndocrinologychemistryAthletesPhysical FitnessPhysical EndurancePhysical therapyFemaleReactive Oxygen SpeciesbusinessOxidative stressJournal of Sports Sciences
researchProduct

Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: evaluation of …

1999

Aims/hypothesis. The aim of this study was to screen part of the putative promoter sequence in addition to 14 potential phosphotyrosine residues of human IRS-2 for genetic variability which might cause changes in protein expression or function. Furthermore, the potential impact on insulin secretion and sensitivity of a previously identified IRS-2 variant (Gly1057Asp) was analysed Methods. The screenings were carried out by the SSCP-heteroduplex technique on DNA from Type II (non-insulin-dependent) diabetic patients. The impact of the Gly1057Asp variant was analysed in four glucose-tolerant Scandinavian study groups. Results. The results showed no nucleotide substitutions in the promoter seq…

AdultMalemedicine.medical_specialtyAdolescentInsulin Receptor Substrate ProteinsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMolecular Sequence Datamedicine.disease_causeGene FrequencyTwo-Hybrid System TechniquesInternal medicineDiabetes mellitusInsulin SecretionInternal MedicinemedicineHumansInsulinGenetic TestingProspective StudiesPhosphotyrosinePromoter Regions GeneticPolymorphism Single-Stranded ConformationalPancreatic hormoneAgedMutationGlucose tolerance testBase Sequencebiologymedicine.diagnostic_testGenetic Carrier ScreeningInsulinIntracellular Signaling Peptides and ProteinsGlucose Tolerance TestMiddle AgedPhosphoproteinsmedicine.diseaseIRS2PedigreeInsulin receptorEndocrinologyAmino Acid SubstitutionDiabetes Mellitus Type 2Insulin Receptor Substrate Proteinsbiology.proteinDiabetologia
researchProduct

Improved identification of heterozygotes for phenylketonuria using blood neopterin and biopterin

1993

A novel approach that combines information provided by the metabolism of pteridines and that of phenylalanine has been applied to the detection of heterozygotes for phenylketonuria. Phenylalanine, tyrosine, biopterin and neopterin have been measured in serum from normal controls and heterozygotes for classical phenylketonuria, before and after a phenylalanine oral load. Significant differences in neopterin and biopterin mean values in fasting serum and in the mean increase of biopterin induced by the phenylalanine load were found between groups. Inclusion of pteridine data in the discriminant analysis significantly improved the resolution of the classical phenylalanine loading test for the …

AdultMalemedicine.medical_specialtyPhenylalanineBiopterinPhenylalanineNeopterinchemistry.chemical_compoundPhenylketonuriasInternal medicineClassical phenylketonuriaGeneticsmedicineHumansTyrosineGenetics (clinical)ChemistryGenetic Carrier ScreeningNeopterinHeterozygote advantageTetrahydrobiopterinBiopterinEndocrinologyTyrosineFemalemedicine.drugPteridineJournal of Inherited Metabolic Disease
researchProduct

The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis

2009

Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) inhibits T-cell activation and interleukin-2 (IL-2) production. The PTPN22(gain-of-function)+1858T(+) genotypes predispose to multiple autoimmune diseases, including early-onset (non-thymomatous) myasthenia gravis (MG). The disease association and the requirement of IL-2/IL-2 receptor signaling for intrathymic, negative T-cell selection have suggested that these genotypes may weaken T-cell receptor (TCR) signaling and impair the deletion of autoreactive T cells. Evidence for this hypothesis is missing. Thymoma-associated MG, which depends on intratumorous generation and export of mature autoreactive CD4(+) T cells, is a model of au…

AdultMalemedicine.medical_specialtyThymomaAdolescentGenotypeThymomaImmunologyBiologymedicine.disease_causePolymorphism Single NucleotideWhite PeopleAutoimmunityPTPN22Young AdultAntigens CDInternal medicineMyasthenia GravisCentral tolerance inductionGeneticsmedicineHumansCTLA-4 AntigenGenetic Predisposition to DiseaseReceptorGenetics (clinical)AgedAged 80 and overT-cell receptorProtein Tyrosine Phosphatase Non-Receptor Type 22Thymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyInterleukin-2FemaleCentral toleranceGenes & Immunity
researchProduct

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late ch…

2007

The introduction of Imatinib (IM) has significantly altered the treatment for CML, although only limited follow-up results are available. As failure of Interferon-alpha had been associated with poor prognosis and results of IM-treatment in this patient group may allow earlier estimation of long-term benefits for early chronic phase patients. Therefore we prospectively analyzed the quality and duration of remissions and the rate of BCR-ABL resistance mutations occurring in patients treated with IM, if they were intolerant or refractory to interferon. Fifty-nine patients were included and median follow up is 4.75 years. Haematologic remission rate was 92% and 62% of patients achieved at least…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classAntineoplastic AgentsBiologyGastroenterologyTyrosine-kinase inhibitorDisease-Free SurvivalPiperazinesMedian follow-upInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase InhibitorsSurvival analysisAgedRetrospective StudiesHematologyImatinibHematologyMiddle Agedmedicine.diseaseSurvival AnalysisLeukemiaImatinib mesylatePyrimidinesImmunologyBenzamidesImatinib MesylateFemaleChronic myelogenous leukemiamedicine.drugAmerican journal of hematology
researchProduct